市場調査レポート
商品コード
1425309

がんバイオマーカーの世界市場レポート 2024年

Cancer Biomarker Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
がんバイオマーカーの世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

がんバイオマーカーの市場規模は近年急速に拡大しています。2023年の197億4,000万米ドルから2024年には227億7,000万米ドルへと、CAGR15.4%で拡大します。過去の期間に見られた拡大は、個別化医療へのシフト、免疫療法の革新、規制の枠組みの進化、共同研究の取り組み、ノンコーディングRNAへの注目の高まりに起因しています。これらの要因の総体として、特定の歴史的時間枠における著しい成長と進歩がもたらされました。

がんバイオマーカー市場は、がんの罹患率の増加によって大きな成長を遂げています。リスク人口10万人当たりの新規がん発生数として測定されるがん発生率の上昇により、がんバイオマーカーが広く使用されるようになりました。これらのバイオマーカーは、疾患リスクの評価、潜伏原発性腫瘍のスクリーニング、良性徴候と悪性徴候の区別、悪性腫瘍の異なる形態の分類において重要な役割を果たしています。注目すべきことに、2022年1月、米国がん協会は、2022年の米国における新規がん患者数は190万人、がんによる死亡者数は60万9,360人と予測されると報告しました。毎日約1,670人の命ががんによって奪われており、がんの罹患率の上昇が当面のがんバイオマーカー市場の成長を牽引すると予想されます。

2023年のがんバイオマーカー市場で最大の地域は北米です。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。がんバイオマーカー市場レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界のがんバイオマーカー市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界のがんバイオマーカーの市場規模実績と成長、2018~2023年
  • 世界のがんバイオマーカー市場規模と成長予測、2023~2028年、2033年

第6章 市場セグメンテーション

  • 世界のがんバイオマーカー市場、バイオマーカータイプ別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • タンパク質バイオマーカー
  • 遺伝的バイオマーカー
  • その他
  • 世界のがんバイオマーカー市場、プロファイリング技術別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • オミクス技術
  • イメージング技術
  • 免疫測定法
  • バイオインフォマティクス
  • 細胞遺伝学
  • 世界のがんバイオマーカー市場、がんのタイプ別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • 乳がん
  • 肺がん
  • 結腸直腸がん
  • 前立腺がん
  • 甲状腺がん
  • 腎臓がん
  • その他のがん
  • 世界のがんバイオマーカー市場、用途別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • 診断
  • 研究開発
  • 予後
  • リスクアセスメント
  • その他

第7章 地域と国の分析

  • 世界のがんバイオマーカー市場、地域別、実績と予測、2018~2023年、2023~2028年、2033年
  • 世界のがんバイオマーカー市場、国別、実績と予測、2018~2023年、2023~2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • がんバイオマーカー市場の競合情勢
  • がんバイオマーカー市場の企業プロファイル
    • F. Hoffmann-La Roche AG
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Illumina Inc.
    • Bio-Rad Laboratories Inc

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の展望と潜在性分析

第35章 付録

目次
Product Code: r12540

Cancer Biomarker Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer biomarker market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer biomarker? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer biomarker market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Biomarkers Type: Protein Biomarkers; Genetic Biomarkers; Other Cancer Biomarkers
  • 2) By Profiling Technologies: Omics Technologies; Imaging Technologies; Immunoassay; Bioinformatics; Cytogenetics
  • 3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Thyroid Cancer; Kidney Cancer; Other Cancers
  • 4) By Application: Diagnostics; Research And Development; Prognostics; Risk Assessment; Other Applications
  • Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; QIAGEN NV; Illumina Inc.; Bio-Rad Laboratories Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

A cancer biomarker is a biological molecule found in blood, tissues, or other bodily fluids that serves as an indicator of normal or abnormal activity and the presence of a specific condition or disease, particularly cancer. These biomarkers are crucial in characterizing alterations within tumors.

The primary types of cancer biomarkers include protein biomarkers, genetic biomarkers, and those utilizing omics technologies, imaging technologies, immunoassay, bioinformatics, and cytogenetics profiling technologies. Protein biomarkers are identifiable markers in a patient's blood that correlate with significant events or signal distinct states in a biological process, such as disease progression. They are employed for accurate disease diagnosis. Cancer biomarkers find applications in various cancer types, including breast cancer, lung cancer, colorectal cancer, prostate cancer, thyroid cancer, kidney cancer, and others. These biomarkers are utilized in diagnostics, research and development, prognostics, risk assessment, and various other applications.

The cancer biomarkers market research report is one of a series of new reports from The Business Research Company that provides cancer biomarkers market statistics, including cancer biomarkers industry global market size, regional shares, competitors with a cancer biomarkers market share, detailed cancer biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the cancer biomarkers industry. This cancer biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer biomarker market size has grown rapidly in recent years. It will grow from $19.74 billion in 2023 to $22.77 billion in 2024 at a compound annual growth rate (CAGR) of 15.4%. The expansion observed in the historical period can be attributed to a shift towards personalized medicine, innovations in immunotherapy, the evolution of regulatory frameworks, collaborative research efforts, and a heightened focus on non-coding RNAs. These factors collectively contributed to significant growth and advancements in the specified historical timeframe.

The cancer biomarker market size is expected to see rapid growth in the next few years. It will grow to $40.66 billion in 2028 at a compound annual growth rate (CAGR) of 15.6%. The anticipated growth in the forecast period can be attributed to a shift towards patient-centric diagnostics, the integration of biomarkers in clinical trials, the emergence of multiplex biomarker panels, exploration of non-coding RNAs, and the commercialization of biomarker tests. Key trends expected in the forecast period encompass advancements in genomics, the adoption of precision medicine approaches, the use of liquid biopsies, innovations in immunotherapy, and the integration of artificial intelligence (AI) in diagnostics and research.

The cancer biomarker market is experiencing substantial growth driven by the increasing incidence of cancer. The rise in cancer incidence rates, measured as the number of new cancers per 100,000 people at risk, has led to a widespread use of cancer biomarkers. These biomarkers play a crucial role in assessing disease risk, screening for occult primary tumors, distinguishing between benign and malignant signs, and categorizing different forms of malignancy. Notably, in January 2022, the American Cancer Society reported an anticipated 1.9 million new cancer cases and 609,360 cancer deaths in the US for 2022. With cancer claiming approximately 1,670 lives each day, the escalating incidence of cancer is expected to drive the growth of the cancer biomarker market in the foreseeable future.

The growth of the cancer biomarker market is further propelled by the increase in the geriatric population. As the percentage of people aged 65 and older rises globally, there is a heightened risk of cancer development among the aging population. This surge in risk amplifies the demand for cancer biomarkers, emphasizing the need for early detection, personalized treatment, and targeted interventions. According to a report by the World Health Organization (WHO) in October 2022, one in six people is projected to be 60 or older by 2030, with the global population of individuals aged 60 years and older expected to reach 2.1 billion by 2050. The increase in the geriatric population is a significant driver for the growth of the cancer biomarker market.

Technological advancement is a prominent trend shaping the cancer biomarker market, with major players adopting advanced technologies like artificial intelligence (AI), deep learning (DL), and machine learning (ML). These technologies address challenges associated with finding cancer biomarkers by processing large volumes of molecular and imaging data beyond the capabilities of traditional statistical studies and tools. For example, in December 2021, F. Hoffmann-La Roche AG introduced uPath Ki-67 (30-9), uPath ER (SP1), and uPath PR (1E2), utilizing pathologist-trained deep learning algorithms for image analysis in breast cancer diagnostics.

Innovation in products, specifically AI-powered cancer diagnostics solutions, is a key focus for major companies in the cancer biomarker market. AI-powered cancer diagnostics leverage advanced computational methods to analyze medical data and aid in the detection, diagnosis, and characterization of cancer. In September 2023, Ibex Medical Analytics launched Galen Breast HER2, an AI-powered solution for HER2 IHC scoring in breast cancer. This solution automates the detection of invasive tumor areas, identifies tumor cells, and calculates the HER2 IHC score with exceptional accuracy. It supports pathologists in achieving precise and consistent HER2 scoring in breast cancer patients.

Strategic acquisitions are also contributing to the evolution of the cancer biomarker market. In May 2021, GE Healthcare acquired Zionexa for an undisclosed amount, expanding its portfolio of neurology and oncology tracers. Zionexa, a France-based company, specializes in developing in-vivo biomarkers for guiding personalized treatments in oncology. This acquisition enhances GE Healthcare's capabilities in providing tailored diagnostic solutions for neurology and oncology.

Major companies operating in the cancer biomarker market report are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMerieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., and Grail Inc.

North America was the largest region in the cancer biomarker market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cancer biomarker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cancer biomarker market consists of sales of epigenetic biomarkers, and metabolic biomarkers for various cancers such as melanoma, leukemia, bladder cancer, non-hodgkin's lymphoma, endometrial cancer, pancreatic cancer, and liver cancer. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Cancer Biomarker Market Characteristics

3. Cancer Biomarker Market Trends And Strategies

4. Cancer Biomarker Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Cancer Biomarker Market Size and Growth

  • 5.1. Global Cancer Biomarker Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Cancer Biomarker Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Cancer Biomarker Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Cancer Biomarker Market Segmentation

  • 6.1. Global Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Protein Biomarkers
  • Genetic Biomarkers
  • Other Cancer Biomarkers
  • 6.2. Global Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Omics Technologies
  • Imaging Technologies
  • Immunoassay
  • Bioinformatics
  • Cytogenetics
  • 6.3. Global Cancer Biomarker Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Thyroid Cancer
  • Kidney Cancer
  • Other Cancers
  • 6.4. Global Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Diagnostics
  • Research And Development
  • Prognostics
  • Risk Assessment
  • Other Applications

7. Cancer Biomarker Market Regional And Country Analysis

  • 7.1. Global Cancer Biomarker Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Cancer Biomarker Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Cancer Biomarker Market

  • 8.1. Asia-Pacific Cancer Biomarker Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Cancer Biomarker Market

  • 9.1. China Cancer Biomarker Market Overview
  • 9.2. China Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Cancer Biomarker Market

  • 10.1. India Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Cancer Biomarker Market

  • 11.1. Japan Cancer Biomarker Market Overview
  • 11.2. Japan Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Cancer Biomarker Market

  • 12.1. Australia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Cancer Biomarker Market

  • 13.1. Indonesia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Cancer Biomarker Market

  • 14.1. South Korea Cancer Biomarker Market Overview
  • 14.2. South Korea Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Cancer Biomarker Market

  • 15.1. Western Europe Cancer Biomarker Market Overview
  • 15.2. Western Europe Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Cancer Biomarker Market

  • 16.1. UK Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Cancer Biomarker Market

  • 17.1. Germany Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Cancer Biomarker Market

  • 18.1. France Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Cancer Biomarker Market

  • 19.1. Italy Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Cancer Biomarker Market

  • 20.1. Spain Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Cancer Biomarker Market

  • 21.1. Eastern Europe Cancer Biomarker Market Overview
  • 21.2. Eastern Europe Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Cancer Biomarker Market

  • 22.1. Russia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Cancer Biomarker Market

  • 23.1. North America Cancer Biomarker Market Overview
  • 23.2. North America Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Cancer Biomarker Market

  • 24.1. USA Cancer Biomarker Market Overview
  • 24.2. USA Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Cancer Biomarker Market

  • 25.1. Canada Cancer Biomarker Market Overview
  • 25.2. Canada Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Cancer Biomarker Market

  • 26.1. South America Cancer Biomarker Market Overview
  • 26.2. South America Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Cancer Biomarker Market

  • 27.1. Brazil Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Cancer Biomarker Market

  • 28.1. Middle East Cancer Biomarker Market Overview
  • 28.2. Middle East Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Cancer Biomarker Market

  • 29.1. Africa Cancer Biomarker Market Overview
  • 29.2. Africa Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Cancer Biomarker Market, Segmentation By Profilling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Cancer Biomarker Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Cancer Biomarker Market Competitive Landscape And Company Profiles

  • 30.1. Cancer Biomarker Market Competitive Landscape
  • 30.2. Cancer Biomarker Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Thermo Fisher Scientific Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. QIAGEN NV
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Illumina Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bio-Rad Laboratories Inc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Cancer Biomarker Market Competitive Benchmarking

32. Global Cancer Biomarker Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Cancer Biomarker Market

34. Cancer Biomarker Market Future Outlook and Potential Analysis

  • 34.1 Cancer Biomarker Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Cancer Biomarker Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Cancer Biomarker Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer